Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization
Raphaël Enaud, Florian Lussac‐Sorton, Éléna Charpentier, Lourdes Velo‐Suárez, Jennifer Guiraud, S. Bui, Michaël Fayon, Thierry Schaeverbeke, Macha Nikolski, the LumIvaBiota Study Group, Pierre‐Régis Burgel, Geneviève Héry-Arnaud, Laurence Delhaès
Abstract
The management of cystic fibrosis has been transformed recently by the advent of CFTR modulators, including lumacaftor-ivacaftor. However, the effects of such therapies on the airway ecosystem, particularly on the microbiota-mycobiota and local inflammation, which are involved in the evolution of pulmonary damage, are unclear.
Topics & Concepts
IvacaftorCystic fibrosisCalprotectinCystic fibrosis transmembrane conductance regulatorMycobiotaMedicineInternal medicineSputumGastroenterologyBiologyPathologyDiseaseInflammatory bowel diseaseTuberculosisEcologyCystic Fibrosis Research AdvancesPediatric health and respiratory diseasesGut microbiota and health